NVP-BKM120 is a highly selective pan-class I phosphatidylinositol-3 kinase (PI3K) inhibitor (23), shown to effectively induce apoptosis in tumor cell lines and animal models of cancer at clinically achievable doses (24–26), and a preliminary clinical trial suggests this agent is well-tolerated (27). This evidence concerns the gene PIK3CA and cancer.